South San Francisco biotechnology company Genentech, makers of some of the world's most boring prescription drugs ever (e.g., supplementary growth hormones Protropin and Nutropin, clot-busting pill TNKase, non-Hodgkins lymphomas treatment Rituxan, and zzzzzzz) might be bought out by Swiss drug company Roche. The European pill-pushers are offering the Bay Area company a whopping $43.7 billion. Genentech, though, is expected "to refuse the bid and strive to remain independent." Or, most likely, turn this offer down and strive to get a higher one.
Join the conversation
Comments
Comments load automatically as this section approaches.